SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression
Z Ding, CJ Wu, GC Chu, Y Xiao, D Ho, J Zhang… - Nature, 2011 - nature.com
Effective clinical management of prostate cancer (PCA) has been challenged by significant
intratumoural heterogeneity on the genomic and pathological levels and limited …
intratumoural heterogeneity on the genomic and pathological levels and limited …
COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis
Mutations in phosphatase and tensin homologue (PTEN) or genomic alterations in the
phosphatidylinositol-3-OH kinase-signalling pathway are the most common genetic …
phosphatidylinositol-3-OH kinase-signalling pathway are the most common genetic …
Critical role of smad2 in tumor suppression and transforming growth factor-β–induced apoptosis of prostate epithelial cells
J Yang, R Wahdan-Alaswad, D Danielpour - Cancer research, 2009 - AACR
Transforming growth factor-β (TGF-β) functions as a tumor suppressor of the prostate
through mechanisms that remain unresolved. Although TGF-β receptors directly activate …
through mechanisms that remain unresolved. Although TGF-β receptors directly activate …
[HTML][HTML] Current mouse and cell models in prostate cancer research
X Wu, S Gong, P Roy-Burman, P Lee… - Endocrine-related …, 2013 - erc.bioscientifica.com
Mouse models of prostate cancer (PCa) are critical for understanding the biology of PCa
initiation, progression, and treatment modalities. Here, we summarize recent advances in …
initiation, progression, and treatment modalities. Here, we summarize recent advances in …
[HTML][HTML] Two sides of the story? Smad4 loss in pancreatic cancer versus head-and-neck cancer
SP Malkoski, XJ Wang - FEBS letters, 2012 - Elsevier
TGFβ signaling Smads (Smad2, 3, and 4) were suspected tumor suppressors soon after
their discovery. Nearly two decades of research confirmed this role and revealed other …
their discovery. Nearly two decades of research confirmed this role and revealed other …
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer
SMAD4 is inactivated in the majority of pancreatic ductal adenocarcinomas (PDAC) with
concurrent mutational inactivation of the INK4A/ARF tumor suppressor locus and activation …
concurrent mutational inactivation of the INK4A/ARF tumor suppressor locus and activation …
Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression
Fibrosis compromises pancreatic ductal carcinoma (PDAC) treatment and contributes to
patient mortality, yet antistromal therapies are controversial. We found that human PDACs …
patient mortality, yet antistromal therapies are controversial. We found that human PDACs …
[HTML][HTML] SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells
YW Chen, PJ Hsiao, CC Weng, KK Kuo, TL Kuo… - BMC cancer, 2014 - Springer
Background SMAD4 is a gastrointestinal malignancy-specific tumor suppressor gene found
mutated in one third of colorectal cancer specimens and half of pancreatic tumors. SMAD4 …
mutated in one third of colorectal cancer specimens and half of pancreatic tumors. SMAD4 …
From transforming growth factor-β signaling to androgen action: identification of Smad3 as an androgen receptor coregulator in prostate cancer cells
Although transforming growth factor-β (TGF-β) has been identified to mainly inhibit cell
growth, the correlation of elevated TGF-β with increasing serum prostate-specific antigen …
growth, the correlation of elevated TGF-β with increasing serum prostate-specific antigen …
Metastasis is driven by sequential elevation of H-ras and Smad2 levels
M Oft, RJ Akhurst, A Balmain - Nature cell biology, 2002 - nature.com
Metastasis is a multistep process that involves local tumour invasion followed by
dissemination to, and re-establishment at, distant sites. Here we show that during multistage …
dissemination to, and re-establishment at, distant sites. Here we show that during multistage …